CN103992400B - 重组人血管内皮抑素的复性液及其制备、使用方法 - Google Patents
重组人血管内皮抑素的复性液及其制备、使用方法 Download PDFInfo
- Publication number
- CN103992400B CN103992400B CN201410235202.4A CN201410235202A CN103992400B CN 103992400 B CN103992400 B CN 103992400B CN 201410235202 A CN201410235202 A CN 201410235202A CN 103992400 B CN103992400 B CN 103992400B
- Authority
- CN
- China
- Prior art keywords
- research
- recombinant human
- solution
- renaturation
- renaturation solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004153 renaturation Methods 0.000 title claims abstract description 161
- 238000011160 research Methods 0.000 title claims abstract description 84
- 108700008165 endostar Proteins 0.000 title claims abstract description 83
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 26
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 83
- 229960003180 glutathione Drugs 0.000 claims abstract description 57
- 235000003969 glutathione Nutrition 0.000 claims abstract description 57
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229960000789 guanidine hydrochloride Drugs 0.000 claims abstract description 29
- 108010024636 Glutathione Proteins 0.000 claims abstract description 26
- 239000002738 chelating agent Substances 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 135
- 239000012460 protein solution Substances 0.000 claims description 30
- 238000000746 purification Methods 0.000 claims description 28
- 230000007850 degeneration Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 22
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 11
- 102400001047 Endostatin Human genes 0.000 description 9
- 108010079505 Endostatins Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000003000 inclusion body Anatomy 0.000 description 7
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235202.4A CN103992400B (zh) | 2014-05-29 | 2014-05-29 | 重组人血管内皮抑素的复性液及其制备、使用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235202.4A CN103992400B (zh) | 2014-05-29 | 2014-05-29 | 重组人血管内皮抑素的复性液及其制备、使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103992400A CN103992400A (zh) | 2014-08-20 |
CN103992400B true CN103992400B (zh) | 2017-01-04 |
Family
ID=51306763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410235202.4A Active CN103992400B (zh) | 2014-05-29 | 2014-05-29 | 重组人血管内皮抑素的复性液及其制备、使用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103992400B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042486A1 (en) * | 1998-02-23 | 1999-08-26 | G.D. Searle & Co. | Method of producing mouse and human endostatin |
WO2000058498A1 (en) * | 1999-03-30 | 2000-10-05 | Merck & Co., Inc. | Soluble recombinant endostatin |
CN1443194A (zh) * | 2000-05-16 | 2003-09-17 | 博尔德生物技术公司 | 含游离半胱氨酸残基的蛋白重折叠的方法 |
WO2007038703A2 (en) * | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc | Il-17a and il-17f antagonists and methods of using the same |
WO2009145489A2 (ko) * | 2008-04-04 | 2009-12-03 | 주식회사 프로셀제약 | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
-
2014
- 2014-05-29 CN CN201410235202.4A patent/CN103992400B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999042486A1 (en) * | 1998-02-23 | 1999-08-26 | G.D. Searle & Co. | Method of producing mouse and human endostatin |
WO2000058498A1 (en) * | 1999-03-30 | 2000-10-05 | Merck & Co., Inc. | Soluble recombinant endostatin |
CN1443194A (zh) * | 2000-05-16 | 2003-09-17 | 博尔德生物技术公司 | 含游离半胱氨酸残基的蛋白重折叠的方法 |
WO2007038703A2 (en) * | 2005-09-28 | 2007-04-05 | Zymogenetics, Inc | Il-17a and il-17f antagonists and methods of using the same |
WO2009145489A2 (ko) * | 2008-04-04 | 2009-12-03 | 주식회사 프로셀제약 | 세포투과성 엔도스타틴 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
Non-Patent Citations (2)
Title |
---|
Acid-Induced Unfolding Mechanism of Recombinant Human Endostatin;Li B.等;《Biochemistry》;20041231(第43期);摘要 * |
Refolding of endostatin from inclusion bodies using high hydrostatic pressure;Chura-Chambi R.M.等;《Analytical Biochemistry》;20081231(第379期);摘要、图1、材料与方法 * |
Also Published As
Publication number | Publication date |
---|---|
CN103992400A (zh) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2743156T3 (es) | Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos | |
US20050209441A1 (en) | Process for promoting proper folding of human serum albumin using a human serum albumin ligand | |
US10052368B2 (en) | Pegylated tissue kallikrein, and preparation method therefor and uses thereof | |
CN103059125B (zh) | 重组人促卵泡激素的纯化方法 | |
PH12015500702B1 (en) | Dialysis a agent comprising acetic acid and acetate, and two-part dialysis agent using same | |
CN106806937A (zh) | 一种止血粉的制备方法 | |
EP3085711B1 (en) | Purification of bacterial capsular polysaccharide by two-phase aqueous micellar system | |
CN111662944A (zh) | 一种人血清白蛋白的制备方法及其纯化方法 | |
CN103992400B (zh) | 重组人血管内皮抑素的复性液及其制备、使用方法 | |
CN101045742B (zh) | 重组人粒细胞集落刺激因子的复性纯化工艺 | |
CN103993058B (zh) | 一种重组人血管内皮抑素的提取纯化方法 | |
US20170114383A1 (en) | Protein production method | |
CN102731658B (zh) | 一种Tat PTD-Endostatin重组蛋白及其制备方法与应用 | |
CN109438585B (zh) | 一种b型嗜血杆菌多糖的纯化工艺 | |
CN111662896A (zh) | 一种粗品尿激酶的纯化方法 | |
CN106834399A (zh) | 一种来源于厚壳贻贝闭壳肌的降压肽 | |
CN105435221B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
CN112280765B (zh) | 磺基甜菜碱表面活性剂在提高菠萝蛋白酶活性中的应用 | |
CN101182475A (zh) | 高效表达弹性蛋白酶的毕赤酵母及其构建方法和应用 | |
CN104531797A (zh) | 一种l-天冬氨酸制取工艺 | |
CN101857871B (zh) | 重组肠道病毒71型病毒vp1抗原的纯化方法 | |
RU2612813C1 (ru) | Способ получения гепарина | |
EP1720896A1 (en) | Process for removing water from aqueous solutions of proteins | |
CN102260189B (zh) | 一种制备n(2)-l-丙氨酰-l-谷氨酰胺的关键中间体n(2)-d-2-氯丙酰-l-谷氨酰胺的方法 | |
CN108822205A (zh) | 一种羊血清白蛋白的提取方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170718 Address after: Cheng Hu Lu, Wuzhong Economic Development Zone of Suzhou City, Jiangsu Province, No. 42 215100 Co-patentee after: Jiangsu Wuzhong Medical Group Co.,Ltd. Patentee after: Jiangsu Wuzhong Group Suzhou Zhongkai Biological Pharmaceutical Co., Ltd. Address before: Cheng Hu Lu, Wuzhong Economic Development Zone of Suzhou City, Jiangsu Province, No. 42 215100 Patentee before: Jiangsu Wuzhong Group Suzhou Zhongkai Biological Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210525 Address after: 310026 a1409-a1410, building 2, 452, No.6 street, Baiyang street, Hangzhou Economic and Technological Development Zone, Zhejiang Province Patentee after: Hangzhou Suoyuan biomedical Co., Ltd Address before: 215100 No.42, Chenghu Road, Wuzhong Economic Development Zone, Suzhou City, Jiangsu Province Patentee before: SUZHOU ZHONGKAI BIOLOGY PHARMACEUTICAL FACTORY, JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Patentee before: JIANGSU WUZHONG PHARMACEUTICAL Group Corp. |
|
TR01 | Transfer of patent right |